Due to the synergistic effect of selinexor combined with a 20S CP inhibitors in pre-clinical trials in MM cells and animal models, selinexor is included in combination therapies with the 3 20S CP inhibitors approved in clinical trials [173,175,176]. This evidence concerns the gene CP and Miyoshi myopathy.